FDA-Approved Peptides: The Complete List (2026)
Most peptides people ask about are not FDA-approved. A smaller set of peptide drugs are, and they are among the most-prescribed medicines in the country. This guide separates the three tiers that get blurred together: FDA-approved peptide drugs, pharmacy-compounded peptides, and research-grade peptides sold with no oversight. It also shows where the July 2026 FDA compounding hearing fits, and why a compounding pathway is not the same thing as drug approval.
Approved, compounded, research: three different things
"Is this peptide FDA-approved?" has three possible answers, and they matter for safety, legality, and quality.
FDA-approved drug. The molecule went through clinical trials for a specific indication, and the finished product is manufactured and reviewed to a fixed standard. Semaglutide and tirzepatide are the headline examples.
Compounded. A licensed pharmacy prepares the drug for an individual patient. The pharmacy is regulated, but the specific formulation is not FDA-reviewed for effectiveness or batch consistency. Compounded semaglutide and sermorelin live here. See compounded semaglutide and compounding pharmacy peptides.
Research-grade. Sold as "not for human use," with no oversight of purity or dosing. Most of the wellness peptide market runs on these. See research peptides and are peptides legal.
FDA-approved GLP-1 and metabolic peptides
The GLP-1 class is where FDA-approved peptides became household names. These are all peptide drugs with approved labels:
- Semaglutide — Ozempic and Rybelsus (type 2 diabetes), Wegovy (weight management). See semaglutide vs Ozempic.
- Tirzepatide — Mounjaro (type 2 diabetes), Zepbound (weight management). A dual GIP/GLP-1 agonist. See tirzepatide vs semaglutide.
- Liraglutide — Victoza (diabetes), Saxenda (weight). See liraglutide for weight loss.
- Dulaglutide — Trulicity (diabetes).
- Exenatide — Byetta and Bydureon (diabetes), the first GLP-1 class drug.
Retatrutide, a triple agonist, is still investigational and not approved. See retatrutide FDA approval and the broader GLP-1 guide for what is coming next.
The broader list of FDA-approved peptide drugs
Peptide drugs reach well beyond metabolism. A representative sample of approved peptide medicines by area:
| Peptide | Brand | Approved use |
|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | Type 2 diabetes, weight management |
| Tirzepatide | Mounjaro, Zepbound | Type 2 diabetes, weight management |
| Tesamorelin | Egrifta | HIV-associated lipodystrophy |
| Setmelanotide | Imcivree | Certain genetic obesity disorders |
| Bremelanotide | Vyleesi | Hypoactive sexual desire disorder |
| Teriparatide | Forteo | Osteoporosis |
| Abaloparatide | Tymlos | Osteoporosis |
| Linaclotide | Linzess | IBS with constipation, chronic constipation |
| Plecanatide | Trulance | Chronic constipation, IBS-C |
| Octreotide | Sandostatin | Acromegaly, certain tumors |
| Lanreotide | Somatuline Depot | Acromegaly, neuroendocrine tumors |
| Icatibant | Firazyr | Hereditary angioedema attacks |
| Enfuvirtide | Fuzeon | HIV-1 infection |
This is not exhaustive, and insulin and glucagon are peptide hormones with a long approval history of their own. The point is simple: the FDA-approved peptides are prescription drugs for defined medical conditions, not the healing, longevity, or cognitive-enhancement compounds that dominate the wellness market.
Growth-hormone peptides: one approved, the rest compounded
This category causes the most confusion because the popular names are not approved drugs. Tesamorelin (Egrifta), a growth-hormone-releasing hormone analog, is FDA-approved, but only for HIV-associated lipodystrophy. See tesamorelin benefits.
Sermorelin was approved as Geref but discontinued for manufacturing reasons, so no approved product exists today; it is compounded only. Ipamorelin, CJC-1295, and hexarelin were never FDA-approved and are research or compounded substances. See sermorelin dosage, CJC-1295 and ipamorelin, and growth hormone peptides.
The approved-drug vs research-peptide split
A single molecule can be both an approved drug and a gray-market peptide, depending on the product. Bremelanotide is FDA-approved as Vyleesi, but the same core compound sold as PT-141 for general libido use is not the approved product and is not FDA-reviewed for that use. The lesson: approval attaches to a specific finished product and indication, not to the peptide sequence in the abstract.
Popular peptides that are NOT FDA-approved
Almost every peptide marketed for healing, recovery, anti-aging, tanning, or cognition falls outside FDA approval:
- BPC-157 and TB-500 — healing and soft-tissue repair claims; not approved.
- GHK-Cu — skin and hair; not approved as a drug.
- MOTS-c, epitalon — metabolism and longevity; not approved.
- Semax, selank — cognition and anxiety; not approved in the US.
- KPV, thymosin alpha-1 — inflammation and immune; not FDA-approved (thymosin alpha-1 is approved abroad as Zadaxin).
For the full picture of what is legal to buy and how enforcement is shifting, see the FDA peptide ban overview and the 14 peptides legal again in 2026.
Where the July 2026 PCAC hearing fits
On July 23-24, 2026 the FDA Pharmacy Compounding Advisory Committee reviewed seven peptides — BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon — for possible addition to the 503A bulks list. Read that carefully: the question was whether pharmacies can legally compound them, not whether they become FDA-approved drugs. Those are different regulatory tracks. A peptide can gain a compounding pathway and still never be an approved drug, and even a favorable committee vote starts a rulemaking process that runs into 2027. Full detail in the PCAC hearing guide.
What "FDA-approved" actually buys you
Approval is not a marketing badge. It means a specific product was tested for a specific use, manufactured under inspected conditions, and carries a label with dosing, contraindications, and known risks. Compounded and research peptides skip most of that. That gap is the practical reason to know which tier a product sits in before using it. If you are weighing peptide therapy, start with peptide therapy, are peptides safe, and where to buy peptides.
Bottom line
The FDA-approved peptides are, overwhelmingly, prescription drugs for diabetes, obesity, bone disease, and a handful of specialty conditions, led by semaglutide and tirzepatide. The peptides driving the wellness market — BPC-157, TB-500, GHK-Cu, MOTS-c, epitalon, and the rest — are not approved, and the July 2026 compounding hearing does not change that even if it opens a legal compounding path. When a product is sold for healing, longevity, or cognition and ships as powder to reconstitute, assume it is not FDA-approved and treat it accordingly.
Frequently Asked Questions About FDA-Approved Peptides
No. BPC-157 is not FDA-approved for any use. It is sold as a research chemical and, until recently, compounded in a regulatory gray area. In September 2023 the FDA placed it in Category 2 of its interim 503A bulk-substance policy, effectively removing regulated compounding access. It is one of seven peptides the FDA Pharmacy Compounding Advisory Committee reviewed on July 23-24, 2026 for a possible legal compounding pathway, which is not the same as drug approval.
Yes on both counts. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are peptide drugs, and both are FDA-approved. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 agonist. These are the most widely used FDA-approved peptides by a wide margin. Compounded versions of the same molecules are a separate category and are not themselves FDA-approved.
An FDA-approved peptide has gone through clinical trials and manufacturing review for a specific indication, and the finished product is what was tested. A compounded peptide is mixed by a pharmacy for an individual patient; the pharmacy is licensed, but the specific formulation is not FDA-reviewed for safety, effectiveness, or manufacturing consistency. A research-grade peptide sold "not for human use" has no oversight of purity or dosing at all.
The molecule bremelanotide is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. PT-141 sold as a research peptide is the same core compound but is not the approved product, is not reviewed for the uses it is marketed for, and is not FDA-approved. This approved-drug-versus-research-peptide split is common: the branded drug is regulated, the gray-market version is not.
Not currently. Sermorelin was FDA-approved as Geref, but the branded product was discontinued in 2008-2009 for manufacturing reasons, not safety. The FDA determined it was not withdrawn for reasons of safety or effectiveness. Today sermorelin is available only through compounding pharmacies, so there is no FDA-approved sermorelin product on the market.
No. Thymosin alpha-1 is marketed internationally as Zadaxin in more than 30 countries, mainly for chronic hepatitis B, but it has never been FDA-approved in the United States. It holds FDA orphan-drug designations for certain conditions, which is not the same as marketing approval. In the US it is a Category 2 substance available only through compounding.
No. The July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting evaluated whether seven peptides should be added to the 503A bulks list, which would create a legal pathway for compounding pharmacies to make them. That is a compounding pathway, not drug approval. A peptide can become legally compoundable without ever being an FDA-approved drug, and even a favorable committee vote triggers months of FDA rulemaking.
Check whether it has a brand name with an FDA-approved label and a National Drug Code tied to an approved application, and whether it is dispensed as a finished prescription drug rather than reconstituted from bulk powder. GLP-1 drugs like Ozempic and Zepbound qualify. Anything sold as "research use only," shipped as lyophilized powder for you to reconstitute, or advertised for uses like healing, anti-aging, or cognition is not an FDA-approved drug.